- Home
- CXAIW vs VCEL Comparison
CXAIW vs VCEL Comparison
Compare CXAIW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXAIW | VCEL |
|---|---|---|
| Founded | N/A | 1989 |
| Country | United States | United States |
| Employees | 41 | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 1.7B |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | CXAIW | VCEL |
|---|---|---|
| Price | $0.04 | $35.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $57.75 |
| AVG Volume (30 Days) | 70.3K | ★ 542.9K |
| Earning Date | 03-21-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | $7,200,000.00 | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.40 |
| Revenue Next Year | N/A | $18.24 |
| P/E Ratio | ★ N/A | $110.89 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $0.02 | $28.95 |
| 52 Week High | $0.13 | $45.97 |
Technical Indicators
Market Signals| Indicator | CXAIW | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 57.65 |
| Support Level | $0.03 | $34.26 |
| Resistance Level | $0.04 | $38.48 |
| Average True Range (ATR) | 0.01 | 1.31 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 55.20 | 94.02 |
Price Performance
Historical ComparisonAbout CXAIW CXApp Inc. Warrant
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.